drugset / Trial / NCT01949857
The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines
Phase 4
Completed
35000 enrolled
Institute of Medical Biology, Chinese Academy of Medical Sciences
Jiangsu Province Centers for Disease Control and Prevention · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of this Phase 4 trial is to assess the safety, immunogenicity, three-year immune persistence of inactivated hepatitis A vaccine (HAV) and live attenuated HAV vaccine.
Timeline
- Start
- 2013-09
- Primary completion
- 2015-12
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Attenuated HAV Vaccine, H2 Strain | Unknown | 6.5 unknown | — |
| Subject | Havrix | Vaccine | 6.5 unknown | — |
| Subject | Hepatitis A Vaccine (Inactivated) | Vaccine | 320 unknown | — |
| Subject | Hepatitis A Vaccine (Inactivated) | Vaccine | 640 unknown | — |
| Subject | Inactivated HAV Vaccine, TZ84 Strain | Unknown | 250 unknown | — |
| Subject | Inactivated HAV Vaccine, TZ84 Strain | Unknown | 500 unknown | — |